BAY2586116
As of the edition of 20 October 2026, BAY2586116 is a drug known only by a code name: of no established status; acts on KCNK3 and KCNK9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 4, 0 stopped early
- Disease areas
- Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bayer | Lead sponsor of trials | 2020 to now |